Biogen Inc. (BVMF:BIIB34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 142.28B +39.2% |
| Revenue (ttm) | 51.84B +1.2% |
| Net Income | 7.16B -7.3% |
| EPS | 48.50 -8.1% |
| Shares Out | n/a |
| PE Ratio | 19.88 |
| Forward PE | 13.19 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 35 |
| Open | 162.24 |
| Previous Close | 162.24 |
| Day's Range | 162.24 - 162.24 |
| 52-Week Range | 113.64 - 172.26 |
| Beta | 0.20 |
| RSI | 53.80 |
| Earnings Date | Apr 29, 2026 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar refe... [Read more]
Financial Performance
In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.
Financial numbers in USD Financial StatementsNews
Biogen resumed with an Outperform at Evercore ISI
Evercore ISI resumed coverage of Biogen (BIIB) with an Outperform rating. Biogen’s recent update “brings a mix of insights regarding the tau program for Alzheimer’s treatment” and while the primary…
Biogen price target raised to $225 from $214 at Piper Sandler
Piper Sandler raised the firm’s price target on Biogen (BIIB) to $225 from $214 and keeps an Overweight rating on the shares. The firm notes Biogen announced that its Phase…
Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push
Biogen NASDAQ: BIIB is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease programs expected to shape the company's next phase of growth, Adam ...
Biogen CELIA topline readout in Alzheimer’s ‘historic,’ says H.C. Wainwright
H.C. Wainwright views Biogen’s (BIIB) CELIA topline results as “historic,” noting that diranersen is the first tau-targeting therapy to demonstrate both replicable tau pathology reduction and directio...
Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
Biogen plans to advance an experimental drug for Alzheimer's disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen plans to move it into Phase 3 t...
Biogen completes acquisition of Apellis Pharmaceuticals
Biogen (BIIB) announced the successful completion of the acquisition of Apellis Pharmaceuticals (APLS). Apellis is now a wholly owned subsidiary of Biogen. In connection with the merger, the shares th...
Biogen’s diranersen shows benefits in early Alzheimer’s Disease
Biogen (BIIB) announced “compelling” topline results from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleotide therapy targeting tau, in individuals with early A...
Ionis announces Biogen’s CELIA study did not meet primary endpoint
Ionis Pharmaceuticals (IONS) announced that its partner, Biogen (BIIB), shared compelling topline results from the Phase 2 CELIA study evaluating diranersen, an investigational antisense oligonucleoti...
Biogen's Alzheimer's Drug Fell Short of Targets. Why the Stock Is Rising Anyway.
Biogen's diranersen showed ‘robust reductions' in key biomarkers during a Phase 2 trial, the biotech said.
Biogen Completes Acquisition of Apellis Pharmaceuticals
CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis, a l...
Biogen up 8% at $220 after Phase 2 diranersen data in Alzheimer’s Disease
07:23 EDT Biogen (BIIB) up 8% at $220 after Phase 2 diranersen data in Alzheimer’s Disease
Biogen's Alzheimer's drug fails to meet mid-stage trial goal
Biogen said on Thursday its Alzheimer's drug did not meet the main goal of a mid-stage trial.
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer's Disease
Robust reductions in tau pathology were observed across all studied doses, with results generally consistent with those observed in the Phase 1b study1 Pre-specified analyses of cognitive endpoints de...
Biogen Transcript: Bank of America Global Healthcare Conference 2026
Immunology is a growing strategic focus, with expertise from MS leveraged to expand into new disease areas. Key pipeline assets like litifilimab and felzartamab target lupus and nephrology, supported by recent business development. Upcoming readouts and a diversified portfolio are expected to drive future growth.
Eisai, Biogen announce FDA extension of review period for lecanemab-irmb sBLA
Eisai (ESAIY) and Biogen (BIIB) announced that the FDA has extended the review period by three months for the supplemental biologics license application, or sBLA, for a once-weekly lecanemab-irmb subc...
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass., May 8, 2026 /PRNewswire/ -- Eisai Co., Ltd.
Remitly Global to replace Apellis in S&P 600 at open on 5/14
Remitly Global (RELY) will replace Apellis Pharmaceuticals (APLS). S&P 500 constituent Biogen (BIIB) is acquiring Apellis Pharmaceuticals in a deal expected to close soon, pending final closing condit...
Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600
NEW YORK, May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14: Bright Horizons Famil...
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Biogen upgraded to Buy from Hold at Freedom Broker
Freedom Broker analyst Ilya Zubkov upgraded Biogen (BIIB) to Buy from Hold with a price target of $245, up from $185. The firm views the company’s acquisition of Apellis (APLS)…
Biogen price target raised to $190 from $189 at Truist
Truist raised the firm’s price target on Biogen (BIIB) to $190 from $189 and keeps a Hold rating on the shares. The firm has updated its model after the company’s…
Biogen price target raised to $200 from $190 at Citi
Citi raised the firm’s price target on Biogen (BIIB) to $200 from $190 and keeps a Neutral rating on the shares. The firm updated the company’s model post the Q1…
Biogen price target raised to $206 from $200 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Biogen (BIIB) to $206 from $200 and keeps an Equal Weight rating on the shares. The company reported a Q1 revenue and…
Biogen price target raised to $222 from $213 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on Biogen (BIIB) to $222 from $213 and keeps an Outperform rating on the shares after its Q1 earnings beat.
Biogen price target raised to $196 from $191 at Wedbush
Wedbush raised the firm’s price target on Biogen (BIIB) to $196 from $191 and keeps a Neutral rating on the shares. While the firm anticipated Q1 would likely be a…